11th Pharmacovigilance 2016
Тези до: 24.11.2016
Дати: 01.12.16 — 01.12.16
Е-мейл Оргкомітету: email@example.com
Організатори: Virtue Insight
After the successful journey of a series of 10 Pharmacovigilance conferences, Virtue Insight is proud to announce its 11th Pharmacovigilance 2016 in India.
It is our great pleasure to invite you to the 11th Pharmacovigilance 2016, in Mumbai - India on 1st of December 2016. We have a wide range of scientific topics with something for everyone.
The past is reflected in a session about Indian traditional medicine and the future is discussed under Big Data analytics and in the research of our young scientists. However, we must live and act in the present and debate pressing challenges that face us today in pharmacovigilance (PV). The rates for medication errors are too high. We still struggle to communicate risk well. With the welcome drive towards transparency and respecting human rights, legal and ethical issues in PV have come to the fore. Society’s research enterprise as a whole needs to become far more aware of the commercial reality that PV underpins safety, with its intimate links to innovation, so that safety and must be intrinsically built into successful development and marketing. With governments round the world struggling to curb healthcare costs, the importance of integrating PV into National Health Programmes has never been more important.
It gives me great pleasure in welcoming all of you to the virtue insight’s 11th Pharmacovigilance 2016. I wish and pray that all our efforts will be beneficial to our industries and to our country at large.
KEY THEMES DISCUSSED AT THIS CONFERENCE:-
Updates - legislation, policies, systems, technology, communication strategies and best practice in PV
Lessons to learn - Pharmacovigilance Programme of India (PvPI)
Clinical Trial Safety: Shift from Explanatory to Pragmatic Trials
Developing pharmacovigilance into high quality management system and its components
Integrate digital health initiative to minimize risks and enhance patient safety
Indigenous medicines for sex selection during pregnancy: How safe is it?
Negotiating Country-Specific annexes and adapting Risk Management Plans (RMPs) to Asia
Developing a refinement of quality in people, process and technology within your PV system
Changing landscape of PV technologies
Assuring certain submission in Patient Support Programs (PSP): Leveraging organizational collaboration to enhance data capture
Understanding the Indian Medical Association (IMA) good practice guide on risk minimization and prevention of medication errors
Mobile Apps to enforce pharmacovigilance and risk minimisation interventions
Using big data to advance drug safety
Negotiating the regulatory environment
Accelerating new medicine introduction in developing world & overcoming challenges
Be part of a major networking opportunity
Веб-сторінка конференції: http://www.virtueinsight.com/pharma/11th-Pharmacovigilance-2016/